[Effect of memantine treatment on patients with moderate-to-severe Alzheimer's disease treated with donepezil]
- PMID: 20201245
[Effect of memantine treatment on patients with moderate-to-severe Alzheimer's disease treated with donepezil]
Abstract
Objective: Investigating the behavioral and cognitive effect of memantine in moderate to severe patients with Alzheimer's disease receiving donepezil.
Material and method: 43 patients were enrolled in this prospective, randomized, parallel group study. There were no significant imbalances between the treatment groups in demographic and baseline clinical characteristics. Cognitive and global measures were collected at baseline and at the end of weeks 4, 8, 12 and 24. Behavioral measures were collected at baseline, at the end of week 12 and at week 24.
Results: Memantine--treated patients showed significantly less deterioration in their functionality. Of patients who exhibited agitation/aggression at baseline, those treated with memantine and donepezil showed significant reduction of symptoms compared with donepezil--treated patients.
Conclusions: Treatment with memantine was well tolerated and reduced agitation/aggression, irritability, and appetite eating disturbances in patients who were agitated at baseline and delazed its emergence in those who were free of agitation at baseline.
Similar articles
-
Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.Neurology. 2006 Jul 11;67(1):57-63. doi: 10.1212/01.wnl.0000223333.42368.f1. Neurology. 2006. PMID: 16832078 Clinical Trial.
-
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.JAMA. 2004 Jan 21;291(3):317-24. doi: 10.1001/jama.291.3.317. JAMA. 2004. PMID: 14734594 Clinical Trial.
-
The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area.Int J Geriatr Psychiatry. 2014 Sep;29(9):881-9. doi: 10.1002/gps.4074. Epub 2014 Jan 17. Int J Geriatr Psychiatry. 2014. PMID: 24436135 Clinical Trial.
-
Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease.Alzheimers Dement. 2013 May;9(3):326-31. doi: 10.1016/j.jalz.2011.11.005. Epub 2012 Oct 27. Alzheimers Dement. 2013. PMID: 23110864 Review.
-
Refining treatment guidelines in Alzheimer's disease.Geriatrics. 2005 Jun;Suppl:14-20. Geriatrics. 2005. PMID: 16025771 Review.
Cited by
-
Alzheimer's Disease Risk and Progression: The Role of Nutritional Supplements and their Effect on Drug Therapy Outcome.Curr Neuropharmacol. 2016;14(2):177-90. doi: 10.2174/1570159x13666150928155321. Curr Neuropharmacol. 2016. PMID: 26415975 Free PMC article. Review.
-
Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis.Int J Neuropsychopharmacol. 2014 Dec 28;18(5):pyu115. doi: 10.1093/ijnp/pyu115. Int J Neuropsychopharmacol. 2014. PMID: 25548104 Free PMC article.
-
NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease.Curr Neuropharmacol. 2012 Sep;10(3):272-85. doi: 10.2174/157015912803217288. Curr Neuropharmacol. 2012. PMID: 23450042 Free PMC article.
-
Present Algorithms and Future Treatments for Alzheimer's Disease.J Alzheimers Dis. 2019;67(4):1157-1171. doi: 10.3233/JAD-180903. J Alzheimers Dis. 2019. PMID: 30741683 Free PMC article. Review.
-
Memantine for dementia.Cochrane Database Syst Rev. 2019 Mar 20;3(3):CD003154. doi: 10.1002/14651858.CD003154.pub6. Cochrane Database Syst Rev. 2019. PMID: 30891742 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical